Teva And Kowa Partner For 50-50 Stake In Japanese Generic Firm
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japanese drug maker Kowa said Sept. 24 that it had signed a definitive agreement with Israel generic manufacturer Teva Pharmaceutical to share a 50-50 stake in a generic manufacturer in Japan to take advantage of a growing Japanese generics market
You may also be interested in...
Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
Battling Negative Image Of Generics In Japan (Part 2 of 2)
[Editor's note: This is part two of a two-part feature on obstacles in promoting generics in Japan. Part one, which explored negative connotations associated with with the term "generic," appeared in PharmAsia News, March 19, 2009.]